These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 19266138)

  • 1. Comparative gastrointestinal safety of weekly oral bisphosphonates.
    Cadarette SM; Katz JN; Brookhart MA; Stürmer T; Stedman MR; Levin R; Solomon DH
    Osteoporos Int; 2009 Oct; 20(10):1735-47. PubMed ID: 19266138
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gastrointestinal tolerability and patterns of switching in patients treated for primary osteoporosis: the Swedish Adherence Register Analysis (SARA).
    Landfeldt E; Lang A; Robbins S; Ström O
    Calcif Tissue Int; 2011 Sep; 89(3):234-45. PubMed ID: 21695544
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk of severe gastrointestinal events in women treated with monthly ibandronate or weekly alendronate and risedronate.
    Blumentals WA; Harris ST; Cole RE; Huang L; Silverman SL
    Ann Pharmacother; 2009 Apr; 43(4):577-85. PubMed ID: 19318598
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differences in persistence among different weekly oral bisphosphonate medications.
    Sheehy O; Kindundu CM; Barbeau M; LeLorier J
    Osteoporos Int; 2009 Aug; 20(8):1369-76. PubMed ID: 19020921
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of the comparative effectiveness of 3 oral bisphosphonates in a large managed care organization: adherence, fracture rates, and all-cause cost.
    Martin KE; Yu J; Campbell HE; Abarca J; White TJ
    J Manag Care Pharm; 2011 Oct; 17(8):596-609. PubMed ID: 21942301
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral bisphosphonate adverse effects in 849 patients with metabolic bone diseases.
    Anastasilakis AD; Goulis DG; Kita M; Avramidis A
    Hormones (Athens); 2007; 6(3):233-41. PubMed ID: 17724008
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tolerability of different dosing regimens of bisphosphonates for the treatment of osteoporosis and malignant bone disease.
    Bobba RS; Beattie K; Parkinson B; Kumbhare D; Adachi JD
    Drug Saf; 2006; 29(12):1133-52. PubMed ID: 17147460
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differences in persistence, safety and efficacy of generic and original branded once weekly bisphosphonates in patients with postmenopausal osteoporosis: 1-year results of a retrospective patient chart review analysis.
    Ringe JD; Möller G
    Rheumatol Int; 2009 Dec; 30(2):213-21. PubMed ID: 19430791
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Common musculoskeletal adverse effects of oral treatment with once weekly alendronate and risedronate in patients with osteoporosis and ways for their prevention.
    Bock O; Boerst H; Thomasius FE; Degner C; Stephan-Oelkers M; Valentine SM; Felsenberg D
    J Musculoskelet Neuronal Interact; 2007; 7(2):144-8. PubMed ID: 17627083
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Efficacy and tolerability of once-weekly administration of 35 mg alendronate and 17.5 mg risedronate].
    Kishimoto H
    Nihon Rinsho; 2007 Nov; 65 Suppl 9():365-8. PubMed ID: 18161133
    [No Abstract]   [Full Text] [Related]  

  • 11. Gastrointestinal and renal side effects of bisphosphonates: differentiating between no proof of difference and proof of no difference.
    Fadda V; Maratea D; Trippoli S; Messori A
    J Endocrinol Invest; 2015 Feb; 38(2):189-92. PubMed ID: 25412945
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Bisphosphonates for osteoporosis].
    Narusawa K; Nakamura T
    Nihon Rinsho; 2007 Nov; 65 Suppl 9():311-5. PubMed ID: 18161123
    [No Abstract]   [Full Text] [Related]  

  • 13. Adherence to and gastrointestinal tolerability of monthly oral or quarterly intravenous ibandronate therapy in women with previous intolerance to oral bisphosphonates: a 12-month, open-label, prospective evaluation.
    Lewiecki EM; Babbitt AM; Piziak VK; Ozturk ZE; Bone HG
    Clin Ther; 2008 Apr; 30(4):605-21. PubMed ID: 18498910
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tolerability of risedronate in postmenopausal women intolerant of alendronate.
    Adachi JD; Adami S; Miller PD; Olszynski WP; Kendler DL; Silverman SL; Licata AA; Li Z; Gomez-Panzani E
    Aging (Milano); 2001 Oct; 13(5):347-54. PubMed ID: 11820707
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk of upper gastrointestinal tract events in risedronate users switched to alendronate.
    Ralston SH; Kou TD; Wick-Urban B; Steinbuch M; Masud T
    Calcif Tissue Int; 2010 Oct; 87(4):298-304. PubMed ID: 20803291
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety considerations with bisphosphonates for the treatment of osteoporosis.
    Strampel W; Emkey R; Civitelli R
    Drug Saf; 2007; 30(9):755-63. PubMed ID: 17722968
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risedronate: a new oral bisphosphonate.
    Umland EM; Boyce EG
    Clin Ther; 2001 Sep; 23(9):1409-21. PubMed ID: 11589256
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of alendronate and risedronate in preventing and treating osteoporosis.
    Peters ML; Leonard M; Licata AA
    Cleve Clin J Med; 2001 Nov; 68(11):945-51. PubMed ID: 11718433
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy, tolerability and safety of once-monthly administration of 75mg risedronate in Japanese patients with involutional osteoporosis: a comparison with a 2.5mg once-daily dosage regimen.
    Hagino H; Kishimoto H; Ohishi H; Horii S; Nakamura T
    Bone; 2014 Feb; 59():44-52. PubMed ID: 24184313
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical efficacy on fracture risk and safety of 0.5 mg or 1 mg/month intravenous ibandronate versus 2.5 mg/day oral risedronate in patients with primary osteoporosis.
    Nakamura T; Nakano T; Ito M; Hagino H; Hashimoto J; Tobinai M; Mizunuma H;
    Calcif Tissue Int; 2013 Aug; 93(2):137-46. PubMed ID: 23644930
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.